Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Chimeric antigen receptor (CAR)-engineered T cells have displayed outstanding performance in the treatment of patients with hematological malignancies. However, their efficacy against solid tumors has been largely limited. In this study, human osteosarcoma cell lines were prepared, flow cytometry using antibodies against CD166 was performed on different cell samples. CD166-specific T cells were obtained by viral gene transfer of corresponding DNA plasmids and selectively expanded using IL-2 and IL-15. The ability of CD166.BBζ CAR-T cells to kill CD166 + osteosarcoma cells was evaluated in vitro and in vivo. CD166 was selectively expressed on four different human osteosarcoma cell lines, indicating its role as the novel target for CAR-T cell therapy. CD166.BBζ CAR-T cells killed osteosarcoma cell lines in vitro; the cytotoxicity correlated with the level of CD166 expression on the tumor cells. Intravenous injection of CD166.BBζ CAR-T cells into mice resulted in the regression of the tumor with no obvious toxicity. Together, the data suggest that CD166.BBζ CAR-T cells may serve as a new therapeutic strategy in the future clinical practice for the treatment of osteosarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In murine models, ALCAM-CAR-T cells inhibited the tumor growth with no obvious toxicity [112].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [112]
The cited source says what the claim attributes to it.
In the citing paper
“ALCAM-CAR-T cells exhibited specific and potent cytotoxicity against human osteosarcoma cells in vitro”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [112]
The cited source says what the claim attributes to it.
In the citing paper
“the cytotoxicity was positively correlated with the level of ALCAM expression on the osteosarcoma cells”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Isakoff, M. S., Bielack, S. S., Meltzer, P., & Gorlick, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4895 · Cited by 1,567
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440
Antitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
Therapeutic T cell engineering
Sadelain, M., Rivière, I., & Riddell, S. (2017) · Nature · doi:10.1038/nature22395 · Cited by 879
Cited by
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J., & Guo, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.024 · Cited by 569
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“In murine models, ALCAM-CAR-T cells inhibited the tumor growth with no obvious toxicity [112].”
BackgroundManaging the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment
Tian, H., Cao, J., Li, B., Nice, E. C., Mao, H., Zhang, Y., & Huang, C. (2023) · Bone Research · doi:10.1038/s41413-023-00246-z · Cited by 232
Belayneh, R., Fourman, M. S., Bhogal, S., & Weiss, K. R. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01053-7 · Cited by 223
Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy
Chulpanova, D. S., Kitaeva, K. V., Green, A. R., Rizvanov, A. A., & Solovyeva, V. V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00402 · Cited by 114
Metadata
- Authors
- Wang, Y., Yu, W., Zhu, J., Wang, J., Xia, K., Liang, C., & Tao, H.
- Affiliations
- Second Affiliated Hospital of Zhejiang University (CN)
- Corresponding author
- Tao, Huimin
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2019-04-17
- Volume
- 38
- Issue
- 1
- Pages
- 168-168
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- PMC
- PMC6471997
- OpenAlex
- W2946233185
- Cited by
- 75
- References
- 50
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 11 · 2023: 15 · 2022: 14 · 2021: 10 · 2020: 9 · 2019: 5
- FWCI
- 3.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81472504)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- osteosarcoma, chimeric antigen receptor T cells, CD166, 4-1BB, CAR T-cell therapy, solid tumor immunotherapy, tumor cell killing, tumor regression, viral gene delivery
- MeSH terms
- Receptors, Chimeric Antigen, Animals, Fetal Proteins, Flow Cytometry, Humans, Interleukin-2, Receptors, Antigen, T-Cell, Osteosarcoma, T-Lymphocytes, Signal Transduction, Antigens, CD, Cell Adhesion Molecules, Neuronal, Gene Expression Regulation, Neoplastic, Immunotherapy, Adoptive, Interleukin-15, Activated-Leukocyte Cell Adhesion Molecule, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, 4-1BB Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. https://app.cochat.ai/papers/10.1186/s13046-019-1147-6
- The paper
- Wang, Y., Yu, W., Zhu, J., Wang, J., Xia, K., Liang, C., & Tao, H. (2019). Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-019-1147-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.